Briviact (in Italy: Nubriveo)
brivaracetam
Table of contents
Overview
Briviact is an epilepsy medicine used as an add-on to other epilepsy medicines to treat partial-onset seizures (epileptic fits starting in one specific part of the brain). It can be used in patients from the age of 2 years with partial-onset seizures with or without secondary generalisation (where the abnormal electrical activity spreads through the brain). Briviact contains the active substance brivaracetam.
-
List item
Briviact : EPAR - Medicine overview (PDF/117.53 KB)
First published: 25/01/2016
Last updated: 17/03/2022
EMA/70742/2022 -
-
List item
Briviact : EPAR - Risk-management-plan summary (PDF/71.03 KB)
First published: 25/01/2016
Last updated: 05/12/2018
Authorisation details
Product details | |
---|---|
Name |
Briviact (in Italy: Nubriveo)
|
Agency product number |
EMEA/H/C/003898
|
Active substance |
Brivaracetam
|
International non-proprietary name (INN) or common name |
brivaracetam
|
Therapeutic area (MeSH) |
Epilepsy
|
Anatomical therapeutic chemical (ATC) code |
N03AX23
|
Publication details | |
---|---|
Marketing-authorisation holder |
UCB Pharma SA
|
Revision |
21
|
Date of issue of marketing authorisation valid throughout the European Union |
13/01/2016
|
Contact address |
Allée de la Recherche 60
1070 Bruxelles Belgium |
Product information
13/03/2023 Briviact (in Italy: Nubriveo) - EMEA/H/C/003898 - IB/0038
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antiepileptics
Therapeutic indication
Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.
Assessment history
News
-
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 January 202228/01/2022
-
01/06/2018
-
20/11/2015